Status:
COMPLETED
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
Lead Sponsor:
Eisai Inc.
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
The primary purpose of this study is to further characterise the hepatotoxicity in participants with advanced or unresectable hepatocellular carcinoma (HCC) treated with lenvatinib, and to further cha...
Eligibility Criteria
Inclusion
- Participants with advanced or unresectable HCC for whom a decision has been made by the treating physician (at their discretion) to initiate lenvatinib or sorafenib treatment, within the prescribing conditions of the approved product label
- Participants must provide signed informed consent to participate in the study within 31 days of initiating treatment with lenvatinib or sorafenib
Exclusion
- None
Key Trial Info
Start Date :
April 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 13 2023
Estimated Enrollment :
335 Patients enrolled
Trial Details
Trial ID
NCT04763408
Start Date
April 9 2021
End Date
December 13 2023
Last Update
July 18 2024
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
California Liver Research Institute
Pasadena, California, United States, 91105
2
Montefiore Medical Center
The Bronx, New York, United States, 10467
3
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390-0001
4
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050